IP Library › Granted Patent US 10,028,973
Granted Patent B2
US 10,028,973 · App. 14/861,428 · Granted Jul 24, 2018

Using DNA methyltransferase inhibitors to treat calcific aorta valve disease

Inventor: Jordan D. Miller (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61K31/706
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,028,973
App. No.
14/861,428
Granted
Jul 24, 2018
Kind
B2
Abstract

Materials and methods for using DNA methyltransferase inhibitors to slow progression of aortic valve calcification and stenosis are provided.

Claims (5)

1. A method for reducing calcific aortic valve stenosis (CAVS) in a patient, comprising administering to a patient identified as having CAVS a therapeutically effective amount of a DNA methyltransferase (DNMT) inhibitor, wherein said CAVS is reduced, and wherein the DNMT inhibitor is an inhibitor of DNA methyltransferase 3b (DNMT3b).

2. The method of claim 1 , wherein the DNMT inhibitor further is an inhibitor of DNA methyltransferase 1 (DNMT1).

3. The method of claim 1 , wherein the DNMT inhibitor further is an inhibitor of DNA methyltransferase 3a (DNMT3a).

4. The method of claim 1 , wherein the DNMT inhibitor is 5-aza-2′-deoxycytidine.

5. The method of claim 1 , wherein the patient is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: MILLER, JORDAN D.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 038350/0741 →
Continuity (2)
Provisional Application 62053406 · Sep 22, 2014
Related Publication 20160082025A1 · Mar 24, 2016